Key facts
- This page summarizes Mark Leonard Singleton's Form 4 filing for Bioventus Inc. (BVS).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 21 Jun 2024, 16:27.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Sale
Additional SEC filing notes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
Reflects shares sold to cover taxes upon the vesting of restricted stock units on June 15, 2024 pursuant to a standing 10b5-1 instruction adopted on March 15, 2024.
Footnote F2
The price reported in Column 4 is a weighted average price calculated by the broker executing the sales transactions. These shares were sold as part of a trade comprised of shares of multiple employees of the Issuer in multiple transactions at prices ranging from $5.525 to $6.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote.